GlaxoSmithKline Pharmaceuticals Limited announced today that the Board of Directors, in a meeting held on March 2nd, 2026, has approved the appointment of Mr. Ronojit Biswas (DIN 07684843) as the Whole-Time Director & Chief Financial Officer (CFO) of the Company. This appointment is for a term of three years, effective from April 1st, 2026. Mr. Biswas is not related to any existing Directors and is not debarred from holding directorship by any authority. He brings over 25 years of extensive experience with GSK across international markets, including leadership roles in India, Vietnam, Singapore, Brazil, and the UK. His most recent role was Senior Finance Director – Global Product Strategy, based in Singapore. He has previously served as CFO for GSK's Brazil and Vietnam businesses and as Regional Controller for GSK's International region. Concurrently, Mr. Juby Chandy, the current CFO, will transition into a new role within the GSK Group. He will step down from his roles as Whole-Time Director and CFO, effective March 11th, 2026, following his promotion to lead APAC Finance within the GSK Group. The company expressed its sincere appreciation for Mr. Chandy's valuable contributions during his tenure. The Board of Directors' meeting commenced at 11:00 am and concluded at 12:00 noon.
